光毒性 - - 药物化学策略,用于降低药物发现中的风险
Tyler J Harrison1, Xin Chen1, Kayo Yasoshima1
1Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.
Journal of medicinal chemistry
|July 14, 2023
概括
药物化学家可以通过在优化过程中使用结构修改和in silico工具来减轻药物光毒性风险. 这种方法有助于确保候选药物的光安全性和监管合规性.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 药理学 药理学是指药理学的学科.
背景情况:
- 光毒性是制药研究中的一个重大安全问题,可能会阻止有前途的候选药物开发.
- 摄影安全评估的监管标准需要积极的战略来解决光毒性责任.
研究的目的:
- 在优化过程中,提供医学化学中光毒性减轻策略的概述.
- 突出结构修改在应对光毒性负债中的作用.
- 为管理光毒性风险的药品化学家提供一个指导工具.
主要方法:
- 在药物化学中用于减轻光毒性的策略的文献综述.
- 分析与光毒基相相关的结构-活性关系.
- 用于光毒性评估的in silico工具和结构警报的描述.
主要成果:
- 结构修改是减轻光毒性的关键策略.
- 形方法和结构警报有助于预测和管理光毒性风险.
- 提出了一个流程图来指导药品化学家通过光毒性风险评估.
结论:
- 药物化学家可以通过明智的结构修改和使用计算工具有效地管理光毒性.
- 积极评估和减轻光毒性对于成功开发药物至关重要.
- 提出的指导工具有助于导航摄影安全评估的监管要求.
相关概念视频
Mutations
38.3K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
38.3K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
234
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
234
Drug Biotransformation: Overview
2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Effects of Chemicals: Overview
1.3K
Drugs, encompassing various chemical compounds from natural sources, lab synthesis, or genetic engineering, elicit different biological responses in living organisms. Some of these responses are desirable or therapeutic, while others are undesirable. The primary goal of administering a drug is to achieve a therapeutic effect, that is, to address a specific disease or health condition. Any concurrent effects outside of this therapeutic outcome are considered undesirable. These undesirable...
1.3K


